A Stanford University School of Medicine study recently published in the Journal of Clinical Investigation, entitled “Prostaglandin signaling suppresses beneficial microglial function in Alzheimer’s disease models,” indicate that microglia impairment may be under the cause of Alzheimer’s disease. The cause of Alzheimer’s disease (AD) is…
Biotech industry veteran Tony Coles, M.D. has launched a new startup — Cambridge, Massachusetts-based Yumanity Therapeutics. Founded in December 2014, the new company’s central focus is on drug discovery for diseases caused by a DNA anomaly called “protein misfolding.” Yumanity Therapeutics’ founders include by Dr. Coles, who is…
A new study on Dementia with Lewy bodies (DLB) and Corticobasal Syndrome (CBS) entitled “Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography” was published in Alzheimer’s Research & Therapy by Michael R Misch, part…
A new study is now enrolling and accepting volunteers to investigate the potential of a new drug to slow the devastating effects of Alzheimer’s disease on patients’ memory and physical activity. Eligible participants include men and women with ages between 55 to 85 years old suffering from mild to severe Alzheimer’s.
A study entitled “Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults,” published this month in Nature Neuroscience, found that a cocoa flavanol containing diet ameliorates cognitive function in older people. The dentate gyrus (DG) is a region in the hippocampal formation whose function…
Scientists at the University of Illinois have created an exciting new method for examining how proteins change their shape right inside cells, using fluorescent markers and a specialized microscope. They recently published their work in the December 1st issue of the journal Public Library of Science One (PLoS…
Recently, a new study presented at the Annual Meeting of the Radiological Society of North America (RSNA) showed that in brains of patients affected with Alzheimer’s disease, changes in brain connections can be visualized by Magnetic resonance imaging (MRI). Alzheimer’s disease is currently estimated to affect approximately 5 million…
A drug that is usually used for treatment of psoriasis has been found to stimulate the activity of the enzyme ADAM10 in the brain of Alzheimer’s patients (AD), providing encouraging results for treating the disease. The study, which was recently published in the journal Neurology, entitled “…
A new study published this week in the Journal of Neuroscience suggests a potential therapy for a type of neurotransmitter receptor for Frontotemporal Dementia. The study entitled ”Tau-Mediated NMDA Receptor Impairment Underlies Dysfunction of a Selectively Vulnerable Network in a Mouse Model of Frontotemporal Dementia,” was…
Eli Lilly and Company and AstraZeneca announced the start of recruitment of patients for the Phase II/III AMARANTH clinical trial of an inhibitor of beta secretes cleaving enzyme (BACE), currently under development as a promising therapy for Alzheimer’s disease. Alzheimer’s disease is characterized by two important pathological features —…
Get regular updates to your inbox.